ALS leaders collaborate to discover connection between ALS, ancient retroviruses
The ALS Association leads the world in research, as it is the only U.S. nonprofit organization that is working against Lou Gehrig’s disease from every angle. The organization offers assistance for ALS patients through its chapter network based throughout the U.S. By uniting its multidisciplinary care, government partnerships and certified clinical care centers, the organization encourages ALS patients with hope for the future.
The Target ALS Foundation aims to create new treatments for the disease. It is a leader in novel, innovation programs for discovering ALS drugs. The company uses collaborative consortia funds specifically dedicated to creating new therapeutic targets.
“Target ALS is excited to partner in this effort to make an unprecedented resource of RNA-seq, whole genome sequencing, detailed clinical and neuropathological dataset as well as the corresponding tissue and biofluid samples immediately available to ALS researchers worldwide,” Target ALS Foundation President Manish Raisinghani said.
The scientists plan to continue gathering and sequencing RNA data taken from tissue samples, as well as induced pluripotent stem cells (iPSCs). Through their partnership, the two organizations intend to improve preventative measures and treatments for the overall outcomes of ALS patients.